2016 Q2 Form 10-Q Financial Statement
#000119312516585251 Filed on May 10, 2016
Income Statement
| Concept | 2016 Q2 | 2016 Q1 | 2015 Q1 |
|---|
Balance Sheet
| Concept | 2016 Q2 | 2016 Q1 | 2015 Q1 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $125.7M | $64.19M | $74.80M |
| YoY Change | 78.56% | -14.19% | -43.59% |
| Cash & Equivalents | $21.93M | $13.42M | $25.44M |
| Short-Term Investments | $103.8M | $50.77M | $49.40M |
| Other Short-Term Assets | $1.200M | $1.000M | $1.200M |
| YoY Change | 33.33% | -16.67% | 9.09% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | $175.0K | ||
| Other Receivables | $0.00 | ||
| Total Short-Term Assets | $127.0M | $65.18M | $76.05M |
| YoY Change | 78.03% | -14.3% | -43.11% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $858.0K | $925.0K | $1.181M |
| YoY Change | -19.59% | -21.68% | -7.59% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | $14.10M | $1.100M | $29.90M |
| YoY Change | -40.51% | -96.32% | 221.51% |
| Other Assets | $230.0K | $160.0K | $175.0K |
| YoY Change | 36.09% | -8.57% | 9.38% |
| Total Long-Term Assets | $15.23M | $2.185M | $31.28M |
| YoY Change | -38.97% | -93.02% | 190.36% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $127.0M | $65.18M | $76.05M |
| Total Long-Term Assets | $15.23M | $2.185M | $31.28M |
| Total Assets | $142.3M | $67.37M | $107.3M |
| YoY Change | 47.71% | -37.24% | -25.7% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $513.0K | $1.294M | $809.0K |
| YoY Change | -50.1% | 59.95% | 13.94% |
| Accrued Expenses | $6.720M | $6.094M | $6.937M |
| YoY Change | 59.51% | -12.15% | 12.12% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $22.95M | $7.388M | $7.746M |
| YoY Change | 337.95% | -4.62% | 9.39% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $131.0K | $144.0K | $181.0K |
| YoY Change | -24.28% | -20.44% | -7.18% |
| Total Long-Term Liabilities | $131.0K | $144.0K | $181.0K |
| YoY Change | -24.28% | -20.44% | -7.18% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $22.95M | $7.388M | $7.746M |
| Total Long-Term Liabilities | $131.0K | $144.0K | $181.0K |
| Total Liabilities | $82.74M | $7.532M | $7.927M |
| YoY Change | 1428.33% | -4.98% | 8.95% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$292.3M | -$282.3M | -$231.8M |
| YoY Change | 19.87% | 21.8% | 25.7% |
| Common Stock | $351.8M | $342.2M | $331.2M |
| YoY Change | 5.08% | 3.31% | 770165.12% |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $59.53M | $59.83M | $99.41M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $142.3M | $67.37M | $107.3M |
| YoY Change | 47.71% | -37.24% | -25.7% |
Cashflow Statement
| Concept | 2016 Q2 | 2016 Q1 | 2015 Q1 |
|---|
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2012Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
20.00 | |
| CY2012Q1 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
150000 | shares |
| CY2016Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
44290506 | shares |
| CY2015Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
25436000 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
9195058 | shares |
| CY2016Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | shares |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
7.79 | |
| CY2016Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2016Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
44290506 | shares |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
2230032 | shares |
| CY2016Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q1 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
150000 | shares |
| CY2016Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
| CY2016Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2016Q1 | us-gaap |
Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
|
0 | Investment |
| CY2016Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
44290506 | shares |
| CY2016Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
342128000 | |
| CY2016Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
446000 | |
| CY2016Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1016000 | |
| CY2016Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
59833000 | |
| CY2016Q1 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
144000 | |
| CY2016Q1 | us-gaap |
Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
|
0 | |
| CY2016Q1 | us-gaap |
Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
|
0 | |
| CY2016Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
471000 | |
| CY2016Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
19000 | |
| CY2016Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1294000 | |
| CY2016Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
6094000 | |
| CY2016Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-282339000 | |
| CY2016Q1 | us-gaap |
Liabilities
Liabilities
|
7532000 | |
| CY2016Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
67365000 | |
| CY2016Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
44000 | |
| CY2016Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
7388000 | |
| CY2016Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2016Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
16000 | |
| CY2016Q1 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
64434000 | |
| CY2016Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
160000 | |
| CY2016Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
3000 | |
| CY2016Q1 | us-gaap |
Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
|
16000 | |
| CY2016Q1 | us-gaap |
Assets
Assets
|
67365000 | |
| CY2016Q1 | us-gaap |
Cash
Cash
|
900000 | |
| CY2016Q1 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
1100000 | |
| CY2016Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
925000 | |
| CY2016Q1 | us-gaap |
Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
|
1100000 | |
| CY2016Q1 | us-gaap |
Assets Current
AssetsCurrent
|
65180000 | |
| CY2016Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
64434000 | |
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
12565000 | |
| CY2016Q1 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
50769000 | |
| CY2016Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
64418000 | |
| CY2016Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
991000 | |
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
13420000 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
10063 | |
| CY2016Q1 | ccxi |
Accrued Liabilities Research And Development Current
AccruedLiabilitiesResearchAndDevelopmentCurrent
|
4161000 | |
| CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
16075000 | |
| CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
7847449 | shares |
| CY2015Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | shares |
| CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
8.52 | |
| CY2015Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2015Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
44185506 | shares |
| CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
2157641 | shares |
| CY2015Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2015Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
150000 | shares |
| CY2015Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
| CY2015Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2015Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
44185506 | shares |
| CY2015Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2015Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
339615000 | |
| CY2015Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
234000 | |
| CY2015Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1908000 | |
| CY2015Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
72507000 | |
| CY2015Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
154000 | |
| CY2015Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
454000 | |
| CY2015Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
1000 | |
| CY2015Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
675000 | |
| CY2015Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
4819000 | |
| CY2015Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-267096000 | |
| CY2015Q4 | us-gaap |
Liabilities
Liabilities
|
5648000 | |
| CY2015Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
78155000 | |
| CY2015Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
44000 | |
| CY2015Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
5494000 | |
| CY2015Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2015Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-40000 | |
| CY2015Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
74806000 | |
| CY2015Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
160000 | |
| CY2015Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
41000 | |
| CY2015Q4 | us-gaap |
Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
|
16000 | |
| CY2015Q4 | us-gaap |
Assets
Assets
|
78155000 | |
| CY2015Q4 | us-gaap |
Cash
Cash
|
1500000 | |
| CY2015Q4 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
5011000 | |
| CY2015Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
949000 | |
| CY2015Q4 | us-gaap |
Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
|
5011000 | |
| CY2015Q4 | us-gaap |
Assets Current
AssetsCurrent
|
72035000 | |
| CY2015Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
74806000 | |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
11340000 | |
| CY2015Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
58455000 | |
| CY2015Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
74846000 | |
| CY2015Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
757000 | |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
12823000 | |
| CY2015Q4 | ccxi |
Accrued Liabilities Research And Development Current
AccruedLiabilitiesResearchAndDevelopmentCurrent
|
2223000 | |
| CY2012Q1 | ccxi |
Warrant Contractual Term
WarrantContractualTerm
|
P10Y | |
| CY2015Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-9683000 | |
| CY2015Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.28 | |
| CY2015Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
8464323 | shares |
| CY2015Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
43502 | shares |
| CY2015Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
106000 | |
| CY2015Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-12006000 | |
| CY2015Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-12109000 | |
| CY2015Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
103000 | |
| CY2015Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
8532000 | |
| CY2015Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
78000 | |
| CY2015Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-11928000 | |
| CY2015Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
103000 | |
| CY2015Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2400000 | |
| CY2015Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
18713000 | |
| CY2015Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
12109000 | |
| CY2015Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
331000 | |
| CY2015Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
8420000 | |
| CY2015Q1 | us-gaap |
Revenues
Revenues
|
0 | |
| CY2015Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
233000 | |
| CY2015Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-509000 | |
| CY2015Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
9361000 | |
| CY2015Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
331000 | |
| CY2015Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3689000 | |
| CY2015Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
23300000 | |
| CY2015Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
61000 | |
| CY2015Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
4051000 | |
| CY2015Q1 | us-gaap |
Depreciation
Depreciation
|
133000 | |
| CY2015Q1 | ccxi |
Non Cash Interest Income Expense Net
NonCashInterestIncomeExpenseNet
|
-471000 | |
| CY2016Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2016Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>1.</b></td> <td valign="top" align="left"><b>Description of Business</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> ChemoCentryx, Inc. (the Company) commenced operations in 1997. The Company is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. The Company’s principal operations are in the United States and it operates in one segment.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Unaudited Interim Financial Information</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The financial information filed is unaudited. The Condensed Consolidated Financial Statements included in this report reflect all adjustments (consisting only of normal recurring adjustments) that the Company considers necessary for the fair statement of the results of operations for the interim periods covered and of the financial condition of the Company at the date of the interim balance sheet. The December 31, 2015 Condensed Consolidated Balance Sheet was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America (GAAP). The results for interim periods are not necessarily indicative of the results for the entire year or any other interim period. The Condensed Consolidated Financial Statements should be read in conjunction with the Company’s financial statements and the notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2015 filed with the Securities and Exchange Commission on March 14, 2016.</p> </div> | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-11115000 | |
| CY2016Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | Segment |
| CY2016Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2016 | |
| CY2016Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
47591 | shares |
| CY2016Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.34 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
|
1725200 | shares |
| CY2016Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9681953 | shares |
| CY2016Q1 | dei |
Document Type
DocumentType
|
10-Q | |
| CY2016Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001340652 | |
| CY2016Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y29D | |
| CY2016Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
|
1750000 | shares |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
3.56 | |
| CY2016Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2016Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
ChemoCentryx, Inc. | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1500200 | shares |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
2.00 | |
| CY2016Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2016-03-31 | |
| CY2016Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates.</p> </div> | |
| CY2016Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
105000 | shares |
| CY2016Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
619000 | |
| CY2016Q1 | dei |
Trading Symbol
TradingSymbol
|
CCXI | |
| CY2016Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
44277 | shares |
| CY2016Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
0 | |
| CY2016Q1 | us-gaap |
Depreciation
Depreciation
|
86000 | |
| CY2016Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
7.71 | |
| CY2016Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
62000 | |
| CY2016Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-15243000 | |
| CY2016Q1 | us-gaap |
Revenues
Revenues
|
0 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
234000 | |
| CY2016Q1 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
|
0 | |
| CY2016Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-15329000 | |
| CY2016Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
86000 | |
| CY2016Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
12714000 | |
| CY2016Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
56000 | |
| CY2016Q1 | us-gaap |
Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
|
0 | |
| CY2016Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
597000 | |
| CY2016Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
210000 | |
| CY2016Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4084000 | |
| CY2016Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
24278000 | |
| CY2016Q1 | ccxi |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Expired Or Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExpiredOrForfeited
|
47591 | shares |
| CY2016Q1 | ccxi |
Share Based Compensation Arrangement By Share Based Payment Award Options Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized
|
0 | shares |
| CY2016Q1 | ccxi |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Options Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantOptionsExercised
|
0 | shares |
| CY2016Q1 | ccxi |
Class Of Warrant Or Right Number Of Warrants Exercised
ClassOfWarrantOrRightNumberOfWarrantsExercised
|
0 | shares |
| CY2016Q1 | ccxi |
Non Cash Interest Income Expense Net
NonCashInterestIncomeExpenseNet
|
-89000 | |
| CY2016Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-15187000 | |
| CY2016Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
86000 | |
| CY2016Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2303000 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
11502000 | |
| CY2016Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
15329000 | |
| CY2016Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
210000 | |
| CY2016Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
11245000 | |
| CY2016Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
1265000 | |
| CY2016Q1 | ccxi |
Share Based Compensation Arrangement By Share Based Payment Award Options Shares Authorized Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesAuthorizedWeightedAverageExercisePrice
|
0 | |
| CY2016Q1 | ccxi |
Available For Sale Securities Debt Maximum Maturities Period
AvailableForSaleSecuritiesDebtMaximumMaturitiesPeriod
|
Less than two years |
